MMP-9 inhibition alleviates postoperative cognitive dysfunction by improving glymphatic function via regulating AQP4 polarity

Int Immunopharmacol. 2024 Jan 5:126:111215. doi: 10.1016/j.intimp.2023.111215. Epub 2023 Nov 23.

Abstract

Postoperative cognitive dysfunction (POCD) is a common complication after surgery, characterized by deficits in memory, attention and cognitive flexibility. However, the underlying mechanisms of POCD remain unclear. Neuroinflammation and blood-brain barrier disruption have been implicated as potential pathological processes. This study explores the neuroprotective effects and mechanisms of the matrix metalloproteinase(MMP-9)inhibitor GM6001 against POCD. We hypothesize GM6001 may reduce neuroinflammation and preserve blood-brain barrier integrity through direct inhibition of MMP-9. Moreover, GM6001 may stabilize aquaporin-4 polarity and glymphatic clearance function by modulating MMP-9-mediated cleavage of dystroglycan, a key protein for aquaporin-4 anchoring. Our results demonstrate GM6001 alleviates postoperative cognitive deficits and neuroinflammation. GM6001 also preserves blood-brain barrier integrity and rescues aquaporin-4 mislocalization after surgery. This study reveals a novel dual role for MMP-9 inhibition in cognitive protection through direct anti-neuroinflammatory effects and regulating aquaporin-4 membrane distribution. Targeting MMP-9 may represent a promising strategy to prevent postoperative cognitive dysfunction by integrating multiple protective mechanisms.

Keywords: AQP4; MMP-9; POCD; Polarity; β-DG.

MeSH terms

  • Aquaporins* / metabolism
  • Blood-Brain Barrier / metabolism
  • Cognitive Dysfunction* / drug therapy
  • Cognitive Dysfunction* / etiology
  • Humans
  • Matrix Metalloproteinase 9 / metabolism
  • Neuroinflammatory Diseases
  • Postoperative Cognitive Complications*

Substances

  • Matrix Metalloproteinase 9
  • Aquaporins